Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)

Furuta, Megumi; Sakakibara-Konishi, Jun; Kikuchi, Hajime; Yokouchi, Hiroshi; Nishihara, Hiroshi; Minemura, Hiroyuki; Harada, Masao; Yamazaki, Shigeo; Akie, Kenji; Fujita, Yuka; Takamura, Kei; Kojima, Tetsuya; Harada, Toshiyuki; Minami, Yoshinori; Watanabe, Naomi; Oizumi, Satoshi; Suzuki, Hiroyuki; Nishimura, Masaharu; Dosaka-Akita, Hirotoshi; Isobe, Hiroshi

Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)

Furuta, Megumi; Sakakibara-Konishi, Jun; Kikuchi, Hajime et al.

The Oncologist, 2019, 24(11), E1172-E1179

Permalink : https://hdl.handle.net/2115/77804

このアイテムのアクセス数:686件（2026-08-14 01:34 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数
Oncologist_24_e1172	pdf	5.00 MB	549
Sakakibara-Konishi Supplementary Figure 1	tiff	484 KB	198
Sakakibara-Konishi Supplementary Figure 2	tiff	696 KB	189
Supplementary Table Oncologist	docx	14.7 KB	114

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/77804
タイトル	Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)
著者	Furuta, Megumi ; Sakakibara-Konishi, Jun ; Kikuchi, Hajime ; Yokouchi, Hiroshi ; Nishihara, Hiroshi ; Minemura, Hiroyuki ; Harada, Masao ; Yamazaki, Shigeo ; Akie, Kenji ; Fujita, Yuka ; Takamura, Kei ; Kojima, Tetsuya ; Harada, Toshiyuki ; Minami, Yoshinori ; Watanabe, Naomi ; Oizumi, Satoshi ; Suzuki, Hiroyuki ; Nishimura, Masaharu ; Dosaka-Akita, Hirotoshi ; Isobe, Hiroshi
e-Rad_Researcher 00848765 著者名 Furuta, Megumi
e-Rad_Researcher 50374278 著者名 Sakakibara-Konishi, Jun
著者名 Kikuchi, Hajime
e-Rad_Researcher 60399946 著者名 Yokouchi, Hiroshi
e-Rad_Researcher 50322805 著者名 Nishihara, Hiroshi
著者名 Minemura, Hiroyuki
著者名 Harada, Masao
著者名 Yamazaki, Shigeo
著者名 Akie, Kenji
著者名 Fujita, Yuka
著者名 Takamura, Kei
著者名 Kojima, Tetsuya
著者名 Harada, Toshiyuki
e-Rad_Researcher 10545445 著者名 Minami, Yoshinori
著者名 Watanabe, Naomi
e-Rad_Researcher 10421968 著者名 Oizumi, Satoshi
e-Rad_Researcher 30322340 著者名 Suzuki, Hiroyuki
e-Rad_Researcher 00208224 著者名 Nishimura, Masaharu
e-Rad_Researcher 70222528 著者名 Dosaka-Akita, Hirotoshi
e-Rad_Researcher 90241322 著者名 Isobe, Hiroshi
言語	英語
キーワード	Small cell lung cancer
	Delta-like protein 3
	Achaete-scute homolog-1
	Immunohistochemistry
	Surgery
発行日	2019-11
出版者	John Wiley & Sons
収録物名	The Oncologist
巻(号)	24(11)
ページ	E1172-E1179
抄録	Background Delta-like protein 3 (DLL3) is a Notch ligand that has an important role in the tumorigenesis of small cell lung cancer (SCLC). Recently, rovalpituzumab tesirine (Rova-T), a DLL3-targeted antibody-drug conjugate, has been developed for treating SCLC. DLL3 is a transcriptional target of the achaete-scute homolog-1 (ASCL1) transcription factor, which is involved in pulmonary neuroendocrine cell development. However, the relationship between DLL3 and/or ASCL1 expression and the clinical features of SCLC remains unknown, especially for early-stage resected SCLC. This study aimed to investigate the expression of DLL3 and ASCL1 in resected SCLC samples using immunohistochemical analysis. Materials and Methods We collected 95 surgically resected SCLC samples, which were formalin fixed and paraffin embedded. Immunohistochemistry staining was performed to investigate the correlation between the expression of either DLL3 or ASCL1 and clinicopathological features of study patients. Results Seventy-seven (83%) of 93 immunohistochemically evaluable samples were positive for DLL3 (expression in >= 1% of tumor cells), and DLL3-high expression (>= 75%) was observed in 44 samples (47%). Sixty-one (64%) of 95 samples were positive for ASCL1 (expression in >= 5% of tumor cells). A positive correlation was observed between DLL3 and ASCL1 expression. DLL3 and ASCL1 expression were not associated with survival in SCLC patients. DLL3 was more prevalent in patients with advanced clinical disease. Conclusion DLL3 and ASCL1 were highly expressed in patients with surgically resected SCLC. DLL3 and ASCL1 may be targets for the treatment of SCLC. Implications for Practice This article examines the relationship between delta-like protein 3 (DLL3) and achaete-scute homolog-1 (ASCL1) protein expression with the clinical features of 95 surgically resected small cell lung cancer (SCLC). DLL3 is attracting attention because rovalpituzumab tesirine (Rova-T), a DLL3-targeted antibody-drug conjugate, was developed recently. DLL3 and ASCL1 were highly expressed in patients with surgically resected SCLC. DLL3 and ASCL1 may be targets for the treatment of early-stage SCLC, including with Rova-T.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
PISSN	1083-7159
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1634/theoncologist.2018-0676